Cancer and Skin Lesions · Journal article

Keratin conversion signature (KRT13/KRT4) defines a high-risk pancreatic cancer subtype with extensive malignant phenotypes

Discover Oncology · September 5, 2026

Promising Why this matters to you Expert discussion

Encouraging direction, but not yet definitive.

AI Summary

A keratin-based prognostic signature (KRT13/KRT4 ratio) was derived from retrospective RNA-seq data and validated in two independent pancreatic cancer cohorts, showing independent association with worse overall survival. The high-risk subtype exhibits aggressive molecular and immune phenotypes, but the biomarker's lack of correlation with chemotherapy sensitivity and absence of prospective clinical trials limit its current clinical applicability.

What was studied

Retrospective cohort study with biomarker discovery and validation. Pancreatic cancer patients; discovery cohort from TCGA-PAAD gemcitabine-treated subset; validation cohorts from TCGA-PAAD full dataset and independent GEO dataset GSE205154.. Intervention: Keratin Switch Score (KSS) based on KRT13/KRT4 expression ratio; risk stratification into high-KSS and low-KSS subtypes.. Compared with: Low-KSS subtype; survival and molecular phenotype comparisons between high and low KSS groups..

Key findings

Multiple keratin genes upregulated in chemotherapy-resistant tumors identified via differential expression analysis KRT13/KRT4-based KSS was independent prognostic factor for worse overall survival in both validation cohorts (TCGA n=183, GEO n=289) High-KSS subtype enriched for E2F targets, hypoxia, epithelial-mesenchymal transition, and p53 pathway activity with higher tumor mutational burden

Safety

Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.

Who this may help

This biomarker may support risk stratification in pancreatic cancer, but cannot yet guide clinical decisions without prospective validation and demonstration of actionability. The lack of chemotherapy sensitivity correlation suggests the signature captures independent biology and may be more relevant for guiding combination or immunotherapy approaches.

Plain-language summary

A novel biomarker derived from retrospective cohort data with validation in two independent datasets, showing consistent association with overall survival in pancreatic cancer, but lacking mechanistic validation or clinical intervention trials to establish actionability.

Study design

As stated by the source record.

MethodsBioinformatics analysis of RNA-seq data identified keratin genes associated with chemotherapy resistance via differential expression and protein interaction analyses in gemcitabine-treated TCGA-PAAD subset (n=62). A Keratin Switch Score (KSS) was constructed via LASSO-Cox regression based on KRT13/KRT4 expression ratio. Prognostic value was validated using Kaplan–Meier and multivariate Cox analyses in full TCGA cohort (n=183) and independent GEO dataset GSE205154 (n=289). Pathway associations, tumor mutational burden, and immune microenvironment were assessed using GSEA, GSVA, and immune deco…

DesignRetrospective cohort study with biomarker discovery and validation

PopulationPancreatic cancer patients; discovery cohort from TCGA-PAAD gemcitabine-treated subset; validation cohorts from TCGA-PAAD full dataset and independent GEO dataset GSE205154.

InterventionKeratin Switch Score (KSS) based on KRT13/KRT4 expression ratio; risk stratification into high-KSS and low-KSS subtypes.

ComparatorLow-KSS subtype; survival and molecular phenotype comparisons between high and low KSS groups.

Reported figures

Quoted from the source exactly as published.

Discovery cohort sample size62

TCGA-PAAD validation cohort sample size183

GEO validation cohort sample size289

Clinical bottom line

Caveats

Retrospective design with potential selection bias; no prospective validation or clinical trial demonstrating treatment benefit stratification
No p-values or confidence intervals reported for primary survival associations; magnitude of prognostic effect not quantified
Biomarker derivation (LASSO-Cox) from same database as one validation cohort raises overfitting concerns
Mechanistic findings (pathway enrichment, immune phenotyping) are correlative and lack independent functional validation

Evidence assessment

Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.

Study design

moderate

Retrospective bioinformatics analysis with validation in two independent cohorts; no randomization or prospective design.

Directness

moderate

Prognostic biomarker for overall survival in pancreatic cancer; clinical utility not yet demonstrated in prospective trials.

Consistency

moderate

KSS prognostic value confirmed in two independent validation cohorts; mechanistic associations with pathways identified but not independently validated.

Risk of bias

limited

Retrospective design with bioinformatics-derived biomarker; no blinding or prospective enrollment; discovery and validation from same database raises overfitting risk.

Sample adequacy

moderate

Discovery n=62; validation cohorts n=183 and n=289; adequate for biomarker validation but modest for generalizable clinical implementation.

Source abstract

Pancreatic cancer has a poor prognosis. This study investigated the prognostic role of the keratin gene family and aimed to develop a keratin-based biomarker. Bioinformatics analysis was performed using RNA-seq data from gemcitabine-treated patients in the TCGA-PAAD cohort (discovery set, n = 62). Differential expression and protein interaction analyses identified resistance-associated keratin genes. A Keratin Switch Score (KSS) was constructed via LASSO-Cox regression based on the KRT13/KRT4 expression ratio. Its prognostic value was validated in the full TCGA cohort (n = 183) and an independent GEO dataset (GSE205154, n = 289) using Kaplan–Meier and multivariate Cox analyses. Associations with pathways, tumor mutational burden, and immune microenvironment were assessed using GSEA, GSVA, and immune deconvolution algorithms. Multiple keratin genes were upregulated in chemotherapy-resistant tumors. The KRT13/KRT4-based KSS was an independent prognostic factor for worse overall survival in both validation cohorts. The high-KSS subtype was enriched for E2F targets, hypoxia, epithelial-mesenchymal transition, and p53 pathway activity, and exhibited higher tumor mutational burden. Its tumor immune microenvironment was characterized by functional suppression (e.g., downregulated T-cell exhaustion genes). KSS did not stably correlate with in vitro sensitivity to gemcitabine or other chemotherapeutics. The KRT13/KRT4 ratio defines a novel, high-risk pancreatic cancer subtype with integrated aggressive tumor cell phenotypes and an immunosuppressive microenvironment. KSS is a robust, independent prognostic biomarker that may guide risk stratification and combination therapy strategies.

Follow from this

Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.

Chen GaoCancer and Skin LesionsZhentao Hou